Press Releases

11 Nov 2022

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

31 Oct 2022

Change of number of shares and votes in Xbrane

28 Oct 2022

Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

28 Oct 2022

Xbrane Biopharma releases interim report for January – September 2022

26 Oct 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

20 Oct 2022

Xbrane Biopharma presents Nomination Committee

18 Oct 2022

Xbrane has carried out a directed share issue raising gross proceeds of approximately SEK 170 million

18 Oct 2022

Xbrane announces intention to carry out a directed share issue

19 Sep 2022

By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022

16 Sep 2022

STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci

07 Sep 2022

Welcome to Xbrane’s Capital Markets Day, including a unique visit to the new research lab, on September 22, 2022

24 Aug 2022

Invitation to Xbrane’s presentation at the Redeye Late-Stage Life Science Event

22 Jul 2022

Xbrane Biopharma releases interim report for January – June 2022

20 Jul 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2022 on July 22, 2022

04 Jul 2022

Xbrane provides update on ranibizumab biosimilar candidate FDA filing

Subscribe to updates regarding Xbrane